SeekingAlpha · Mar 6, 2026
RC
NASDAQ · RCKT
Rocket Pharmaceuticals, Inc.
Healthcare · Biotechnology
$3.62
Up+$0.15 (+4.01%)
Updated Aug 28, 2026, 4:16 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 372.83M
- P/E ratio
- -1.6
- Dividend yield
- 0.00%
- 52-week range
- $2.53 – $5.45
- Volume
- 1.26M
- Avg. volume
- 2.37M
Price performance
RCKT price history
1M range · 21 trading sessions · Daily adjusted prices
RCKT closed at $3.62 after 21 trading sessions, up 12.77% for the selected period.
- Last close
- $3.62
- Period change
- +12.77%
- Period low
- $3.11
- Period high
- $3.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $3.63 | $3.76 | $3.59 | $3.62 | 1.26M |
| Aug 26, 2026 | $3.73 | $3.73 | $3.58 | $3.66 | 1.12M |
| Aug 25, 2026 | $3.54 | $3.81 | $3.5359 | $3.78 | 2.2M |
| Aug 24, 2026 | $3.53 | $3.55 | $3.375 | $3.53 | 913.3K |
| Aug 21, 2026 | $3.52 | $3.605 | $3.48 | $3.51 | 939.79K |
| Aug 20, 2026 | $3.60 | $3.659 | $3.43 | $3.48 | 1.11M |
| Aug 19, 2026 | $3.41 | $3.66 | $3.40 | $3.65 | 1.44M |
| Aug 18, 2026 | $3.33 | $3.421 | $3.27 | $3.34 | 1.09M |
| Aug 17, 2026 | $3.47 | $3.47 | $3.36 | $3.40 | 1.51M |
| Aug 14, 2026 | $3.33 | $3.50 | $3.27 | $3.47 | 1.16M |
| Aug 13, 2026 | $3.42 | $3.446 | $3.31 | $3.34 | 1.11M |
| Aug 12, 2026 | $3.49 | $3.55 | $3.40 | $3.41 | 954.05K |
| Aug 11, 2026 | $3.66 | $3.67 | $3.37 | $3.50 | 1.7M |
| Aug 10, 2026 | $3.60 | $3.7099 | $3.54 | $3.64 | 1.36M |
| Aug 7, 2026 | $3.53 | $3.615 | $3.465 | $3.61 | 1.32M |
| Aug 6, 2026 | $3.52 | $3.62 | $3.49 | $3.54 | 2.12M |
| Aug 5, 2026 | $3.46 | $3.52 | $3.38 | $3.50 | 1.98M |
| Aug 4, 2026 | $3.39 | $3.53 | $3.33 | $3.44 | 2.08M |
| Aug 3, 2026 | $3.13 | $3.475 | $3.03 | $3.41 | 3.17M |
| Jul 31, 2026 | $3.185 | $3.21 | $3.05 | $3.11 | 1.28M |
| Jul 30, 2026 | $3.14 | $3.21 | $3.11 | $3.21 | 1.13M |
Latest RCKT news
The latest Smart Investors Daily articles mentioning RCKT.
Stock researchCompany · Overview
RCKT research
Overview
Company profile and research snapshot.
Company profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Wedbush | Outperform | — |
| May 11, 2026 | Chardan Capital | Buy | — |
| Mar 30, 2026 | B of A Securities | Buy | — |
| Mar 27, 2026 | Chardan Capital | Buy | — |
| Mar 2, 2026 | Goldman Sachs | Sell | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 2, 2026
Goldman Sachs Maintains Sell on Rocket Pharmaceuticals, Raises Price Target to $3
Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Sell and raises the price target from $2 to $3.
Benzinga · Feb 27, 2026
Rocket Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS results. Also, Cantor Fitzgerald raised its price target on the stock from $8 to $10.
Benzinga · Feb 27, 2026
Cantor Fitzgerald Maintains Overweight on Rocket Pharmaceuticals, Raises Price Target to $10
Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target from $8 to $10.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
